A phase I, multi-center, open label, dose escalation trial of safety and pharmacokinetics of intravenous PR-104 given every 3 weeks in patients with solid tumours
Phase of Trial: Phase I
Latest Information Update: 29 Nov 2012
At a glance
- Drugs PR 104 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 01 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Apr 2008 Status changed from recruiting to in progress according to ClinicalTrials.gov.
- 09 Feb 2007 New trial record.